Silke Kapp‐Schwoerer
Klinikum Ludwigshafen(DE)University Hospital Ulm(DE)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation(2019)120 cited
- → Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial(2020)117 cited
- → Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group(2019)113 cited
- → Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study(2019)107 cited
- → DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia(2017)66 cited
- → Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial(2023)54 cited
- → Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)(2022)26 cited
- → Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease(2023)14 cited
- → Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial(2025)13 cited
- → 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting(2022)13 cited